China's drug regulator has accepted a New Drug Application for Telix's PSMA PET imaging agent Illuccix, supported by a positive China Phase 3 trial. This moves China toward joining the US, EU and others where PSMA PET is standard in advanced prostate cancer care. Over coming decades, broader PSMA imaging and related theranostics could materially change staging, treatment selection and survival for Chinese patients and influence global radiopharmaceutical markets.
Verdict: China's NMPA CDE has formally accepted an NDA for TLX591-Px (Illuccix) based on a pivotal Chinese Phase 3 study that met its primary endpoint with a 94.8% positive predictive value (Telix, 2026-01-20; PRNewswire, 2026-01-20).([telixpharma.com](https://telixpharma.com/news-views/chinese-nmpa-accepts-new-drug-application-for-illuccix-for-prostate-cancer-imaging/?utm_source=openai)) Prostate cancer incidence in China is rising about 6% annually, and PET/CT capacity has expanded rapidly, supporting significant clinical demand (Telix, 2026-01-20; Laotian Times, 2026-01-20).([telixpharma.com](https://telixpharma.com/news-views/chinese-nmpa-accepts-new-drug-application-for-illuccix-for-prostate-cancer-imaging/?utm_source=openai)) Positive Phase 3 data and multi-region approvals suggest PSMA PET will diffuse widely, but timelines for Chinese approval, reimbursement and real-world practice change remain uncertain (Nasdaq, 2025-12-21; The Motley Fool Australia, 2026-01-20).([nasdaq.com](https://www.nasdaq.com/articles/telix-reports-positive-phase-3-results-illuccix-prostate-cancer-imaging-trial-china?utm_source=openai))
NMPA grants approval within about 18 months and reimbursement follows quickly, enabling broad access in major cities. PSMA PET rapidly becomes standard for staging and biochemical recurrence, leading to earlier detection of metastases and more appropriate use of surgery, radiotherapy and systemic treatments. Survival and quality-of-life improvements mirror or exceed outcomes seen in early-adopting Western health systems.
Regulatory review proceeds on a typical timeline of roughly two to three years, with initial reimbursement limited to higher-risk indications and tertiary centres. Uptake grows first in large urban hospitals, constrained by scanner availability, radiopharmaceutical logistics and training, then gradually diffuses to provincial centres. Over 5-10 years, PSMA PET becomes routine for many, but not all, clinically eligible patients in China.
Regulatory or pricing hurdles delay approval or reimbursement well beyond expectations, slowing adoption. Supply-chain bottlenecks in gallium generators, isotopes or radiopharmacy capacity limit scan throughput, even in centres that want to adopt. Competing priorities and budget pressures reduce the share of eligible Chinese patients who actually receive PSMA PET, blunting its population-level impact.
Alternative imaging modalities or tracers, potentially including AI-enhanced MRI protocols or non-PSMA PET agents, achieve comparable or superior performance at lower cost. China backs domestic alternatives through industrial policy, limiting Illuccix's role to niche segments or research. Over time, global standards bifurcate, with some regions anchored on PSMA PET and others on different imaging paradigms.
Developments: By early 2027, the NDA dossier will be under active review at NMPA, with clarifying questions and potential on-site inspections under way. Leading Chinese oncology centres will begin planning for possible PSMA PET workflows, including staff upskilling and radiopharmacy capacity assessments. International data, guideline updates and real-world evidence will continue to strengthen the perceived clinical value of PSMA PET.
Risks: Any safety signals, manufacturing issues or data inconsistencies could slow or complicate the review. Hospitals that invest early may face sunk costs if approval or reimbursement is delayed. Competing capital needs, such as other imaging or therapeutic technologies, could crowd out preparatory investments for PSMA PET.
Outlook: Regulatory and institutional positioning dominates this phase. Stakeholders gather information, plan infrastructure and watch for NMPA feedback. Patient access remains limited to clinical trials and outbound medical tourism.
Developments: By 2028, it is plausible that initial marketing authorization is granted for Illuccix in China, at least for biochemical recurrence and selected staging indications. A limited set of tertiary centres in major cities will begin offering PSMA PET routinely, with early adoption driven by academic oncologists and urologists. Domestic manufacturers and distributors will move to build partnerships and localized supply where possible.
Risks: If reimbursement is restricted or set too low, patient out-of-pocket costs could limit access. Uneven geographic distribution of PET/CT scanners may widen regional disparities in diagnosis and treatment. Early operational problems, such as scheduling bottlenecks or tracer shortages, could create skepticism among clinicians or administrators.
Outlook: China likely enters the PSMA PET era with focused, urban-centred availability. Clinical enthusiasm grows, but systemic and financial barriers keep utilization below potential. Evidence from early adopters helps refine protocols and economic arguments.
Developments: Around 2029, PSMA PET will likely be embedded in clinical pathways at leading cancer centres across China's largest metropolitan regions. Referral patterns from secondary hospitals into PSMA-capable centres will solidify, improving staging and recurrence assessment for a growing share of patients. Early data on treatment-plan modification rates and outcomes in Chinese practice will emerge, informing guideline updates.
Risks: Workforce shortages in nuclear medicine and radiopharmacy could slow throughput gains, even where hardware exists. Emerging domestic PSMA tracers might fragment the market, complicating training and standardization. Health system budget constraints, especially in less affluent provinces, may cap further expansion without targeted funding policies.
Outlook: Urban networks see tangible clinical benefits and build experience. Expansion beyond top-tier cities becomes the key question for equity and total impact. Policy decisions on reimbursement and capacity distribution strongly influence the next phase.
Developments: By 2031, PSMA PET is likely standard in major urban centres and expanding steadily into secondary cities, especially where PET/CT fleets have grown. Radioligand therapies targeting PSMA, already used in some countries, may enter or expand in China, tying imaging and treatment decisions more tightly together. Research collaborations between Chinese and international centres will generate large datasets to refine risk stratification and therapy selection.
Risks: If radioligand therapies remain expensive or tightly rationed, expectations created by precise imaging may not translate into proportional treatment access. Concerns about radiation exposure or long-term safety could trigger public or regulatory scrutiny. A rapid influx of competing radiopharmaceuticals might strain regulatory capacity and create confusion over optimal sequencing.
Outlook: China moves closer to a mature PSMA-based imaging and therapy ecosystem. Benefits concentrate in systems able to fund both diagnostics and advanced treatments. Strategic choices about pricing, reimbursement and domestic innovation determine how widely those benefits spread.
Developments: By 2036, PSMA PET and related biomarkers are likely embedded from initial staging through recurrence and advanced disease in Chinese guidelines. Combined imaging-genomic risk scores may guide personalized therapy, including surgery, radiation, systemic agents and PSMA-targeted radioligands. Expanded PET/CT and cyclotron infrastructure will reduce regional gaps, though urban-rural disparities may persist.
Risks: If demographic aging and rising incidence outpace capacity growth, waiting times for imaging and treatment could lengthen. Budget pressures might force difficult prioritization among oncology innovations, affecting PSMA-linked care. International tensions over isotope supply chains or intellectual property could disrupt radiopharmaceutical availability.
Outlook: Prostate cancer management in China becomes far more imaging-driven and stratified. Many patients benefit from more precise staging and targeted therapies. Remaining gaps hinge on system-level capacity and financing rather than core technology performance.
Developments: By 2046, PSMA PET or its successors will operate within AI-augmented diagnostic workflows that automatically quantify disease burden and predict outcomes. Longitudinal datasets from millions of scans will support continuous refinement of treatment algorithms and health-economic models. China's radiopharmaceutical industry may evolve into a major exporter, leveraging scale and experience gained from domestic adoption.
Risks: Algorithmic bias or opaque decision tools could introduce new inequities or errors if not properly validated. Dependence on complex digital infrastructure raises cybersecurity and outage risks. If cost-containment dominates health policy, advanced imaging and theranostics might be limited to a subset of patients, despite technical feasibility for wider use.
Outlook: Imaging becomes deeply integrated with data science and personalized oncology. China stands as both a major user and potential supplier of advanced radiopharmaceutical solutions. Ethical, regulatory and financing choices determine whether benefits are equitably distributed.
Developments: By 2076, prostate cancer imaging may rely on multi-target, multi-modality platforms that far exceed current PSMA PET capabilities. The Illuccix era will be seen as an important step in normalizing molecular imaging-guided care in large, complex health systems like China's. Radiopharmaceutical and non-radioactive molecular imaging may converge, offering dynamic, whole-body views of tumour biology in real time.
Risks: Longevity of earlier generations of radiopharmaceutical facilities could pose decommissioning and environmental challenges. Shifts in disease patterns or successful prevention strategies might reduce prostate cancer burden, altering the value proposition of specific imaging pathways. Global inequities in access to advanced diagnostics and therapies could persist even if technology becomes routine in wealthy regions.
Outlook: Molecular imaging remains central to cancer care, though specific targets and modalities evolve. Decisions made in the 2020s and 2030s about infrastructure, training and regulation continue to shape capabilities. The main uncertainty is how health systems balance innovation, cost and fairness over multiple technology generations.